Welcome to our dedicated page for Pediatrix Medical Group news (Ticker: $MD), a resource for investors and traders seeking the latest updates and insights on Pediatrix Medical Group stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pediatrix Medical Group's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pediatrix Medical Group's position in the market.
Pediatrix Medical Group, Inc. reported earnings of $0.05 per share for the first quarter of 2024, with Adjusted EPS of $0.20. Net revenue was $495 million, net income was $4 million, and Adjusted EBITDA was $37 million. The company focused on operating efficiency and margin stabilization. Same-unit revenue increased by 2.3%, driven by patient volume growth. Expenses rose for clinical compensation and internal staffing. Adjusted EBITDA decreased to $37.2 million. Cash and cash equivalents were $8.0 million, with total debt of $705 million. The company expects 2024 Adjusted EBITDA to be $200-220 million.